Context Therapeutics Inc’s filing revealed that its Chief Executive Officer Lehr Martin A. acquired Company’s shares for reported $70080.0 on Jun 09 ’25. In the deal valued at $0.70 per share,100,000 shares were bought. As a result of this transaction, Lehr Martin A. now holds 920,190 shares worth roughly $0.62 million.
Then, Levit Alex C. bought 20,000 shares, generating $11,520 in total proceeds. Upon buying the shares at $0.58, the Chief Legal Officer, Corp. Sec now owns 29,000 shares.
Before that, Minai-Azary Jennifer Lynn bought 40,010 shares. Context Therapeutics Inc shares valued at $25,486 were divested by the Chief Financial Officer at a price of $0.64 per share. As a result of the transaction, Minai-Azary Jennifer Lynn now holds 80,010 shares, worth roughly $53606.700000000004.
William Blair initiated its Context Therapeutics Inc [CNTX] rating to an Outperform in a research note published recently. A number of analysts have revised their coverage, including JMP Securities’s analysts, who began to cover the stock in early January with a ‘”a Mkt outperform”‘ rating. D. Boral Capital began covering CNTX with “Buy” recommendation on November 25, 2024. Piper Sandler started covering the stock on May 16, 2024. It rated CNTX as “an Overweight”.
Price Performance Review of CNTX
On Tuesday, Context Therapeutics Inc [NASDAQ:CNTX] saw its stock fall -4.89% to $0.67. Over the last five days, the stock has gained 14.86%. Context Therapeutics Inc shares have fallen nearly -36.33% since the year began. Nevertheless, the stocks have fallen -61.80% over the past one year.
How much short interest is there in Context Therapeutics Inc?
A steep rise in short interest was recorded in Context Therapeutics Inc stocks on 2025-05-15, dropping by 70616.0 shares to a total of 2.27 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-15 was 2.35 million shares. There was a decline of -3.1%, which implies that there is a negative sentiment for the stock.
